Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

ESH CLL 2020 | Cellular and non-cellular immunotherapies in CLL

Matthew Davids • 20 Nov 2020
ESH CLL 2020
Chronic Lymphocytic Leukemia Leukemia Antibodies Ibrutinib

Matthew Davids, MD, Dana-Farber Cancer Institute, Boston, MA, outlines the use of cellular and non-cellular immunotherapies in chronic lymphocytic leukemia (CLL) as discussed at the annual ESH CLL meeting, including updates on the use of CAR T-cell therapies in CLL. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Matthew Davids

Developing and testing a tandem CD19/ROR1 CAR-NK to overcome apoptotic resistance in CLL 1:21
Developing and testing a tandem CD19/ROR1 CAR-NK to overcome apoptotic resistance in CLL
Matthew Davids • 8 Dec 2025
Fixed-duration and MRD-adapted therapy in CLL: insights from ASH 2025 2:08
Fixed-duration and MRD-adapted therapy in CLL: insights from ASH 2025
Matthew Davids • 8 Dec 2025
Mutation-guided finite-duration AV after first-line BTKi+ven-based therapy in CLL/SLL: MAVRiC trial 1:27
Mutation-guided finite-duration AV after first-line BTKi+ven-based therapy in CLL/SLL: MAVRiC trial
Matthew Davids • 8 Dec 2025
Strategies being explored for the potential management of monoclonal B-cell lymphocytosis 0:47
Strategies being explored for the potential management of monoclonal B-cell lymphocytosis
Matthew Davids • 13 Sep 2025

Related Videos

MRD-guided treatment with ibrutinib and venetoclax in previously untreated CLL: analyses of FLAIR 7:15
MRD-guided treatment with ibrutinib and venetoclax in previously untreated CLL: analyses of FLAIR
Talha Munir • 16 Dec 2025
Real-world outcomes of olutasidenib in IDH1-mutated AML previously treated with venetoclax 2:14
Real-world outcomes of olutasidenib in IDH1-mutated AML previously treated with venetoclax
Jorge Cortes • 7 Dec 2025
Patient-reported outcomes from ASC4FIRST study of asciminib in newly diagnosed CML 2:22
Patient-reported outcomes from ASC4FIRST study of asciminib in newly diagnosed CML
Jorge Cortes • 7 Dec 2025
Preliminary human data and clinical implications of asciminib administration during pregnancy in CML 5:08
Preliminary human data and clinical implications of asciminib administration during pregnancy in CML
Elisabetta Abruzzese • 5 Dec 2025
The content of VJHemOnc is intended for healthcare professionals